Studies on rodents have indicated that those with 60% deficiency of CB1R in the hypothalamus are less sensitive to a non-nutritive effect of rimonabant (a selective agonist of CB1R, previously used as an anti-obesity treatment and then excluded due to multiple adverse reactions, mostly psychiatric). Here, CNR1 is linked to Obesity.